This is something we will discuss next week at the AMR meeting in Philadelphia
关于我们
MBF Therapeutics is an immunotherapeutics company focused on animal applications of its innovative T-Max™ immunotherapeutic DNA vaccine platform. In addition, there are significant translational opportunities in human health. Our T-Max platform addresses longstanding shortcomings of traditional viral vaccine technologies based primarily on killed/inactivated (KWV) whole virus or modified live/attenuated virus vaccines (MLV/AV). Killed virus vaccines have been fairly safe but not efficacious, while MLV vaccine must replicate to generate reasonable efficacy and therefore have significant safety issues for the vaccinated animal and also the herd because of chronic carriers and viral shedding. MBFT will create safe and efficacious vaccines focused on respiratory viral diseases that cause significant negative economic and social impacts. Specifically Porcine Reproductive and Respiratory Syndrome (PRRS) considered the most economically significant disease of worldwide swine production; and African Swine Fever (ASF), a highly fatal and reportable disease that has caused billions of dollars lost due to death/cull of millions of pigs and disrupted markets and trade throughout Asia, Europe, Africa and now threatens the US with an estimated cost impact of 50 billion dollars in lost trade and containment costs. T-Max Plasmid DNA Vaccine Platform MBFT’s T-Max™ DNA vaccine platform is a proprietary process from discovery to commercialization of protective vaccines that identifies clinically relevant pathogen antigens and delivers them in proprietary formulations to stimulate durable and potent T cell immune responses. Four components differentiate the platform: 1. Novel antigen selection process to identify multiple clinically relevant antigens to create cross-protective ”universal” vaccines; 2. Cloning into proprietary plasmids containing a non-antibiotic selection system; 3. One or more immunomodulators that stimulate a strong innate immune response; and 4. CaptaVa
- 网站
-
http://www.mbftherapeutics.com
MBF Therapeutics Inc.的外部链接
- 所属行业
- 生物技术
- 规模
- 2-10 人
- 类型
- 私人持股
- 创立
- 2008
- 领域
- Canine Oncology、Infectious Diseases和Swine vaccines
地点
MBF Therapeutics Inc.员工
动态
-
The key will be the development of safe and effective non-modified live virus vaccines to effectively address this issue.
Turkey, egg and dairy groups call for new approach to avian flu
feedstuffs.com
-
Excited to be speaking at the Disease Prevention & Control Summit 2024 in Philadelphia! 150+ speakers, 1,500+ attendees, and cutting-edge insights await. Don't miss out on early bird rates ending Aug 9th - save $200! https://lnkd.in/ez6zQFff #DiseasePreventionSummit
Register for the Disease Prevention & Control Summit 2024 | Sept 5 -6
i.snoball.it
-
My thanks to the World Trade Center Philadelphia for the invitation to participate in the meeting with Chairman of the China Council for the Promotion of International Trade, Tianjin Sub-Counsel. A very interesting and informative meeting in a market that is important to our future commercial plans.
-
-
We were invited to the World Vaccine Congress to speak during the One Health section. This provided us an opportunity to also outline how our T-Max platform also meets the need for an "ideal human health" vaccine by HHS-NIH-NIAID-BAA2024-1 in their Development of Vaccine Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections, and Emerging Infectious Diseases”.
-
-
I greatly appreciate my friend Dr. Yimy Mena of Pegasus Biotech, sharing this picture of me presenting at the World Vaccine Congress. This provided MBFT with another opportunity to demonstrate that our T-Max platform is meeting our goal of addressing the need for an "ideal vaccine" for the animal health market.
-